132686-96-5 Usage
Classification
Thienodiazepine derivative
Sedative
It has a calming effect on the central nervous system.
Anxiolytic
It helps reduce anxiety and stress.
Amnestic
It can cause memory impairment.
Mechanism of Action
Acts as a potent agonist at the benzodiazepine receptor, enhancing the inhibitory effect of the neurotransmitter gamma-aminobutyric acid (GABA) in the central nervous system.
Medical Uses
a. Treatment of anxiety disorders.
b. Management of panic attacks.
c. Treatment of insomnia.
Recreational Use
Known for its euphoric and relaxing effects, but associated with a high potential for dependence and addiction.
Legal Status
Classified as a controlled substance in many countries due to its abuse potential and adverse effects when misused.
Appearance
Typically comes in the form of a white or off-white crystalline powder.
Dosage Forms
Available as tablets, capsules, or oral solutions.
Onset of Action
Rapid, with effects felt within 30 minutes to 2 hours after ingestion.
Duration of Action
Effects typically last for 4-6 hours, depending on the dosage and individual factors.
Metabolism
Metabolized in the liver by the cytochrome P450 system.
Excretion
Primarily eliminated through the kidneys in the form of metabolites.
Side Effects
Can include drowsiness, dizziness, muscle relaxation, and impaired coordination. More severe side effects may include respiratory depression, coma, and death in cases of overdose.
Check Digit Verification of cas no
The CAS Registry Mumber 132686-96-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,2,6,8 and 6 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 132686-96:
(8*1)+(7*3)+(6*2)+(5*6)+(4*8)+(3*6)+(2*9)+(1*6)=145
145 % 10 = 5
So 132686-96-5 is a valid CAS Registry Number.
132686-96-5Relevant articles and documents
The treatment of HIV-1 infection using certain pyridodiazepines
-
, (2008/06/13)
Disclosed are novel pyridodiazepines. These compounds, as well certain known 6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepin-5-ones are useful in the treatment of AIDS, ARC and related disorders associated with HIV infection.
Novel Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. 1. Tricyclic Pyridobenzo- and Dipyridodiazepinones
Hargrave, Karl D.,Proudfoot, John R.,Grozinger, Karl G.,Cullen, Ernest,Kapadia, Suresh R.,et al.
, p. 2231 - 2241 (2007/10/02)
Novel pyridobenzodiazepinones (I), pyridobenzodiazepinones (II), and dipyridodiazepinones (III) were found to inhibit human immunodeficiency virus type 1 (HIV-1) reverse transcriptase in vitro at concentrations as low as 35 nM.In all three series, small substituents (e.g., methyl, ethyl, acetyl) are preferred at the lactam nitrogen, whereas slightly larger alkyl moieties (e.g., ethyl, cyclopropyl) are favored at the other (N-11) diazepinone nitrogen.In general, lipophilic substituents are preferred on the A ring, whereassubstitution on the C ring generally reduces potency relative to the corresponding compounds with no substituents on the aromatic rings.Maximum potency is achieved with methyl substitution at the position ortho to the lactam nitrogen atom; however, in this case an unsubstituted lactam nitrogen is preferred.Additional substituents on the A ring can be readily tolerated.The dipyridodiazepinone derivative 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyridodiazepin-6-one (96, nevirapine) is a potent (IC50 = 84 nM) and selective non-nucleoside inhibitor of HIV-1 reverse transcriptase, and has been chosen for clinical evaluation.
